Concord Biotech Acquires 26% Stake in Clean Max to Advance Sustainability Initiatives

Concord Biotech Limited, a leading biopharma company specializing in fermentation-based Active Pharmaceutical Ingredients (APIs), has announced its decision to acquire a 26% equity stake in Clean Max, a prominent renewable energy solutions provider. This strategic investment underscores Concord Biotech's commitment to sustainability and reducing its carbon footprint by integrating renewable energy into its operations.

By partnering with Clean Max, Concord Biotech aims to enhance its energy efficiency and promote environmental responsibility within the pharmaceutical manufacturing sector. This move aligns with global trends emphasizing sustainable industrial practices and reflects Concord Biotech's dedication to corporate social responsibility.

Source: Official company announcement.